With a new grant from the National Institutes of Health, an Oklahoma Medical Research Foundation scientist will look at Alzheimer’s disease from a different angle.
Heather Rice, Ph.D., will look for links between the deadly, memory-robbing disease and a protein that historically has been linked to cancer.
Rice will collaborate on the two-year study with scientist Xin Zhang, Ph.D., from the University of Oklahoma Health Sciences Center. Zhang studies a protein called CD151, which has been associated with tumor metastasis and other aspects of cancer.
Zhang has found that the protein may be interacting with another protein, amyloid precursor protein or APP, which has been heavily implicated in the development of Alzheimer’s. Rice’s own lab at OMRF focuses on better understanding APP, with the hope of developing strategies to prevent it from breaking down and accumulating in the brain.
The pair hope to uncover new information about the interplay between the two proteins. “Ultimately, we believe their interaction may prevent overproduction of the protein fragments that lead to Alzheimer’s,” Rice said.
In the longer term, such studies could pave the way for new treatments for Alzheimer’s, which accounts for 60% to 80% of all types of dementia. The disease is caused by damage to the brain’s nerve cells.
This damage is believed to begin at least 20 years before the onset of symptoms such as difficulty with memory and other thinking skills. According to the Alzheimer’s Foundation, the condition affects more than 10% of people 65 and older and is the fifth-leading cause of death in that age group.
“Despite a lot of effort, we do not yet have an effective treatment for Alzheimer’s,” said Benjamin Miller, Ph.D., who chairs OMRF’s Aging & Metabolism Research Program. “Dr. Rice’s proposed research takes advantage of a funding mechanism for high-risk, high-reward ideas, which illustrates her outside-the-box thinking toward potential treatments.”
Rice’s grant, No. 1R21AG085486-01, was awarded by the National Institute on Aging, part of the NIH. A team science grant from the Presbyterian Health Foundation funded early studies that made the NIH grant possible.
